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A size distribution between 200 and 300 nm and a high drug entrapment is desirable for liposomes 
intended for topical application. In an early phase of drug development, small batch sizes are also 
wanted. Dual Asymmetric Centrifugation (DAC) meets these requirement and was our method of 
choice. But, after successful production of a few DAC-liposome batches with drug entrapment of 
chloramphenicol (CAM) > 50%, vesicle size 200-300 nm, batch size approx. 500 µl, high lipid 
content of 40-50% (w/v), the DAC-machine got broken. Thus, probe-sonication was replacing 
DAC, with the following alterations: (1) The sample volume was increase from 500 µl to between 
2 and 8 ml (2) Lipid concentration was reduced from semisolid VPGs to liquid dispersions; 10, 20 
and 30 mg/ml lipid conc. in sonicated samples. The efficiency of the DAC method was 
significantly improved when adding propylene glycol (PG), reducing the needed processing time 
from 50 min to 2 min and 55 seconds. We therefore wanted to investigate (3) the effect of PG-
concentration on the sonication method (levels of between 50 and 200 µl PG was added). Finally, 
(4) number of 2-minutes sonication cycles was judged critical, and between 2 and 6 cycles were 
tested. Empty liposomes were produced from Lipoid S-100 and variables investigated using 
multifactorial design on two levels (+1/-1), plus center points. The design matrix, given by the 
Unscramble 9.8 software, gave 19 experiments in a (24) full factorial design. The liposome size 
distribution varied from 55.8 to 408 nm, except one experiment giving liposome sizes of 876 nm. 
The ANOVA analysis suggest that within the levels of the variables investigated, sample volume is 
the most important variable affecting the vesicle size (p-value 0.0145), and number of sonication 
cycles (p-value 0.0692). Of the 19 experiments, four experiments had the aimed vesicle size of 
200-300 nm, and were repeated with CAM added. CAM entrapped in sonicated liposomes was 
between 23 and 31%, and lower that for the DAC-liposomes (around 50%). An increase in vesicle 
size was observed when adding CAM for three out of four formulations (mean diameter 769, 837 
and 834 nm and 67 nm). Both DAC and probe-sonication are suitable for making liposomes with 
the aimed vesicle size of 200-300 nm, and with acceptable incorporation efficiency of CAM. For 
CAM-liposomes, sonication conditions applied in this experimental matrix is too gentle and 
liposome size bigger than aimed for. Effect of PG on liposome size from sonication could not be 
demonstrated with the applied PG concentrations.   
 
Keywords: Drug delivery system; liposome; probe sonication; multivariate analysis; statistical 







En liposom-størrelsesfordeling mellom 200-300nm og en høy legemiddelinkorporering 
karakteristika som er ønskelige for liposomer beregnet for topikal administrering. I de 
tidligste legemiddelutviklingsfasene er små batchstørrelser også ønskelig. Dual 
Asymmetric Centrifugation (DAC) innfrir disse kravene, og var metoden som ble valgt for 
studien. Etter en vellykket produksjon av et noen DAC-liposom batcher 
(legemiddelinkorporering av kloramfenikol (CAM) > 50%, vesikkelstørrelse på 200-
300nm, batchstørrelse på ca 500 µl, høyt lipidinnhold på rundt 40 til 50% (w/v), ble DAC-
apparatet ødelagt. En ny lipidstørrelsesreduksjonsmetode, nemlig «probe sonication». 
Følgende endringer ble ansett som nødvendig ved overgang fra DAC til «probe sonication» 
ble valg istede for DAC, med følgende endringer: (1) Prøvevolume ble økt fra 500 µL til 
mellom 2 og 8 mL. (2) Lipidkonsentrasjonen ble redusert fra vesikulære fosfolipid geler 
(VPGs) i DAC til flytende dispersjoner med mellom 10-30 mg/ml lipidkonsentrasjon i 
probe-sonikeringen. Siden effektiviteten av DAC-metoden var vesentlig forbedret ved 
tilsetning av propylenglykol (PG), og medførte en drastisk reduksjon av den nødvendige 
sentrifugeringstid fra 50 minutter til 2 minutter og 55 sekunder, ønsket vi å undersøke (3) 
virkning av PG-konsentrasjonen på sonikeringsmetoden (nivåer på mellom 50 og 200uL 
PG til liposomdispersjon). Avslutningsvis (4) antall sonikeringsrunder som varte i 2 
minutter ble ansett som kritisk for den oppnådde vesikkelstørrelsen. Mellom 2 til 6 
sykluser ble utprøvd. Tomme liposomer ble fremstilt fra Lipoid S-100 og variabler som ble 
undersøkt ved hjelp av multifaktorielt-design på to nivå (+1/-1), i nivåene som ble 
beskrevet ovenfor, i tillegg til midtpunktene. Den resulterende designmatrisen som angitt 
av Unscramble 9.8 software, ga 19 eksperimenter i 24 full faktoriell design. 
Liposomstørrelsesfordelingen varierte fra 55,8 til 408nm, og med et forsøk som ga en 
liposomstørrelse på 876nm. ANOVA analyse tydet på at det innenfor nivåene av de målte 
variablene er prøvevolumet den viktigste faktorene som påvirker størrelsen(p-verdi 
0,0145), og antallet sonikeringssykluser(p-verdi: 0,0692). Fire av forsøkene hadde det 
tilsiktede vesikkelstørrelsen på 200 til 300nm, og var gjentatt med CAM. CAM inkorporert 
i sonikerte liposomer var mellom 23 og 31%, og var lavere enn for DAC-liposomene 
(omtrent 50%). Dette kan forklares med den høyere lipidkonsentrasjonen i DAC prøvene. 
Det ble observert en signifikant økning i vesikkelstørrelsen når man legger til CAM i 3 av 
fire formuleringer (gjennomsnittsdiameter 769, 837 og 834 nm, og 67nm). Inkoporeringen 
av CAM inn i det ytre bilipidlaget og en mer rigid membranstruktur kan forklare den økte 




fremstillingen av liposomer med den ønskede vesikkelstørrelsen på 200-300nm, og  med 
en akseptabel inkorpoeringseffektivitet av CAM. For CAM-liposomer, er 
sonikeringsbetingelser som ble brukt i dette forsøksmatrisen for skånesomme og 
liposomstørrelse er større enn den ønsket størrelsen. Effekten av PG på liposom-størrelse 
fra sonikeringen kunne ikke påvises med de brukte PG-konsentrasjonene.  
 
Nøkkelord: Drug delivery system; liposome; probe sonication; multivariate analysis; 
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Liposomes, or lipid vesicles, are formed when membrane-forming lipids, such as 
phospholipids, are dispersed in aqueous media (Vemuri and Rhodes, 1995). Liposomes are 
proven suitable for drug incorporation and sustained drug delivery for systemic application 
and intravenous administration, but also for topical use. When administrated topically, 
liposome composition and physiochemical properties will decide the fate of the drug and the 
liposomal carrier (Taylor et al., 2005). 
 
It has earlier been concluded that for deposition of drug onto the strata of the skin, and for 
minimal systemic drug uptake and side-effects, the optimal liposome size is approximately 
300 nm in diameter (du Plessis et al., 1994). At the same time, as much as possible of the drug 
should be inside the liposomes to achieve the wanted sustained release effect.  
 
In lab scale liposome production, screening different formulations, it is desirable to use 
production methods that are suitable for making small batch sizes (taking the high expenses 
of the raw material into account), easy to apply, fast, gentle, non-expensive, and easy to 
control. However, conventional methods usually contain several (time consuming) steps. In 
this study, we wanted to take a closer look at the final, and critical step in the production of 
liposomes, namely the size reducing step. Probe sonication is applied to reduce the size of the 
liposomes formed after hydration of lipids, most often hydrated from a dried lipid film, 





1.1. Liposomes as drug delivery system 
Liposomes are spherical vesicles that consist of an aqueous core surrounded by phospholipid 
(PL) bilayers (as shown in Figure 1). They are spontaneously formed when phospholipids are 
brought in contact with an aqueous medium. The size of the liposomes may range from tens 
of nanometers to tens of microns in diameter (Papahadjopoulos and Kimelberg, 1974). 
 
Liposomes have the ability to function as drug carrier for both hydrophilic and lipophilic 
drugs. The hydrophilic drugs can be incorporated into the aqueous core, while the lipophilic 




Figure 1: Liposomes with lipophilic drug incorporated into the lipid bilayer and 
hydrophilic drug incorporated in the aqueous core (Figure used with permission) 





1.2. Liposomes in Topical Drug Delivery  
The properties of liposomes as drug carrier system, depends on several factors; (1) the 
physiochemical properties of their membranes, (2) the nature of their components, (3) 
liposome size, (4) surface charge and (5) lipid organization (Elsayed et al., 2007). In topical 
application, liposomes are usually entrapped into a vehicle to achieve suitable viscosity and 
application properties. The size of the liposomes will influence the properties of topical 
liposomal dosage form (Skalko et al., 1998). 
 
The most important obstacle for topical drug administration is the low diffusion rate of drugs 
through the stratum corneum. Several methods have been estimated to increase the 
permeation rate of drugs temporarily. One of the most promising approaches is application of 
drug in vesicles based on formulations (Bouwstra and Honeywell-Nguyen, 2002). The 
optimal liposomes size for topical administration is expected to be approximately 300 nm (du 
Plessis et al., 1994).  
 
Several properties make liposomes attractive as drug delivery system, such as (Torchilin, 
2005): 
- Biocompatibility and non-toxicity.  
- Ability to entrap both hydrophilic and hydrophobic pharmaceutical agents. 
- Capability to reduce toxicity and increased stability of entrapped drug. 
 
1.3. Phospholipids in Liposomes Products  
Phospholipids (PL) are obtained from two major sources, soy beans and egg yolk (Brandl, 
2001). When phospholipids are dispersed in aqueous medium, they have a strong tendency to 
form membranes. This is because their polar heads prefer to interact with the aqueous 
medium, whereas their long aliphatic chains encourage interaction with one another. 
Hydrophobic interactions, the Van der Waal forces keep the long hydrocarbon tail together 
when lipid bilayer is formed (Papahadjopoulos and Kimelberg, 1974).  
 
Phosphatidycholine (PC), has the chemical structure drawn in Figure 2, is the most commonly 
used phospholipid in preparation of liposomes.  It can be obtained from both natural and 
synthetic sources. PC consists of a polar group which is represented by the quaternary 
ammonium moiety choline, that is linked to a glycerol back bone by a phosphoric ester, the 
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other two hydroxyl groups of the glycerol backbone are esterified with fatty acids of different 




Figure 2: Chemical structure of phosphatidylcholine (Brandl, 2001). 
 
The hydrocarbon chain length and the degree of saturation of the acyl chains influence the 
transition temperature (Tm), where the membrane transforms from a rigid, “gel state” to a 
liquid crystalline state. The fluid phase is the more flexible and permeable phase of the lipid 
membrane, and more suitable for transition of water over the lipid bilayer. The fluidity or 
mobility of the lipid layer is determined by whether and to which degree non-lipid drugs may 
be encapsulated into or adsorbed onto the membrane (Brandl, 2001). 
 
Table 1:  Overview of the most common phospholipids 
Name of phospholipid The esterified group Abbreviation Net charge at pH 7.0 
Phosphatidic acid -H PA Negative 
Phosphatidylcholine -CH2CH2N
+(CH3)3 PC Zwitterionic 
phosphatidylethanolamine -CH2CH2NH3
+ PE Zwitterionic 
Phosphatidylglycerol -CH2CHOHCH2OH PG Negative 
Phosphatidylinositol -HC6H5(OH)5 PI Negative 
Phosphatidylserine -CH2CHNH3+COO






Table 1 is shown the most common PLs, their most common used abbreviations, and the 
esterifies group that characterizes the different PLs, and also give them the net charge 
important for inducing electrostatic repulsion and stabilization of liposome dispersions 
(Ogihara et al., 2010).  
PC is consisting of a phosphoric choline head group, a centerpiece of glycerin and a tail with 
two different fatty acid (R´= fatty acid), as illustrated in figure 1 (Hasengschwandtner, 2005).  
 
1.4. Classification and Size Reduction of Liposomes  
1.4.1. Liposomes Classification  
Liposomes can be classified based on the preparation method used, the lipid composition, size 
and lamellarity (New, 1990, Samad et al., 2007). 
According to the method of preparation liposomes may vary in their size and lamellarity 
(New, 1990), respectively. 
 Unilamellar vesicles (ULV) – 25-100 nm in diameter.  
 Small unilamellar vesicles (SUV) – they are single bilayer vesicles, around 25-50 nm 
in size. These are most common to use in intravenous/parenteral drug delivery due to 
their homogeneous in size range.  
 Large unilamellar vesicls (LUV) – these are large single bilayer vesicles of more than 
100 nm in diameter. They can entrap a high amount of hydrophilic drug due to their 
large aqueous compartment compared with SUVs. 
 Multilamellar vesicles (MLV) – they consist of a large number concentric lamellar, 
due to their large lamellarity bilayers single bilayer vesicles, of 100 nm to several 
micrometer in diameter.  
 Multivesicular vesicles (MVV) – more than 1000 nm in diameter.   
 
Figure 3 gives a visual explanation on how we see the different liposomes classes, explained 






Figure 3: Schematic representation of small and large unilamellar vesicles (SUV/LUV), 
multilamellar vesicle (MLV) and multivesicular vesicles (Salim et al., 2014). 
 
1.4.2. Sonication 
Sonication is a simple method for size reduction in preparation of liposomes (Woodbury et 
al., 2006). There are two types of sonication methods; probe sonication and bath ultrasonic 
disintegrator (New, 1990). When high-intensity ultrasound is applied to aqueous dispersion of 
polar lipids it may lead to formation of small lipid vesicles (Richardson et al., 2007). The 
probe tip sonicator delivers high energy to lipid dispersion that may overheat the lipid 
dispersion and causes degradation (New, 1990).  Spontaneous generation and collapse of 
small cavities shows when the sound waves are spreading through aqueous dispersion polar 
lipid with frequencies between 16 and several hundred kHz (Taylor et al., 2005). 
 
Sonication is, due to its speed and simplicity, one of the most commonly used methods to 
reduce the original vesicle size to ensure the desire size, lamellarity and homogeneity 
properties of liposomes (Woodbury et al., 2006).  
Advantages: 
 Ability to produce smaller liposomes (Müller et al., 2004). 
 Can be performed directly on hydrated MLVs (Taylor et al., 2005). 
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 Effective for reduction of large MLVs to more homogenous dispersion of SUVs 
(New, 1990) (Barenholz et al., 1977). 
 
 
However, some disadvantages exist for the method, accordingly;  
 High-energy input during sonication lead to high risk of oxidation of the 
phospholipids (Müller et al., 2004). 
 Direct contact between sample and sonication probe cause possible metal impurities in 
the sample.  
 Poor reproducibility (New, 1990). 
 Require constant cooling (New, 1990). 
 
Size distribution and lamellarity of liposome after sonication have been investigated in several 
studies (Müller et al., 2004).  Frequency and power are the most important parameters of 
ultrasound, but the ultrasound characteristics also described to be directly dependent on power 
input and duration of sonication (Silva et al., 2010). When comparing the effect of ultrasound 
of different frequencies the faster reduction of mean size vesicle is achieved at the lower 
frequency (Yamaguchi et al., 2009).  
 
1.4.3. Liposomes Size Reduction by Dual Asymmetric Centrifugation (DAC) 
Dual asymmetric centrifugation (DAC) is method that can be used for homogenization and 
reduction of particle size for liposomes as previous reported by Massing and his group 
(Massing et al., 2008). This method is a specific kind of centrifugation method. The major 
difference of DAC from normal centrifugation is that the vial is turned around its own centre 
when normal centrifugation is processed. According to this the backward rotation of the 
sample lead to an overlaid agitation of the inward and outward movement of the sample 
(Figure 4). Due to adhesion between the sample material and the rotating vial, the 
centrifugation around its own centre pushes the sample in the opposite direction. DAC is 
performed in a sealed vial, a design that makes it suitable for sterile production of liposomes 
or also suitable to entrap toxic/radioactive compounds. Glass beads are used to increase the 







Figure 4: Schematic picture of the principle of dual asymmetric centrifuging (Massing et 
al., 2008). 
 
The advantages of using DAC for homogenization liposomes dispersion are;  
 DAC is suitable for producing small batches of VPGs and subsequently, liposome 
dispersion in a standard injection vial under sterile conditions. 
 DAC is simple and gentle with respect to sensitive substances (Tenambergen et al., 
2013). 
 Reproducible method (Massing et al., 2008). 
 High entrapment efficiency for hydrophilic drugs due to the same amount of water 
outside and inside of the liposomes (Massing et al., 2008).   
 
Limitations might be that only viscous liposome formulations are suitable to be size reduced 
by DAC, as the homogenization effect depends on the sample to adhere to the rotating vial 
surface.  Vesicular phospholipid gels (VPGs) are very concentrated liposomal dispersion, 
where the liposomes form a three dimensional network, and have a viscous consistence 
(Massing et al., 2008). VPGs therefore are the preferred liposomal intermediate applied in the 




1.5. Size Analysis of Liposomes  
Several techniques are used for determination of liposomes size and size distribution, such as 
photo correlation spectroscopy (PCS), electron microscopy, size exclusion chromatography 
(SEC), analytic ultracentrifugation, sedimentation field flow fractionation and small angle X-
ray diffraction and scattering (Grabielle-Madelmont et al., 2003, Hupfeld et al., 2006). In this 
project, PCS was the method of choice. 
 
1.5.1. Photon Correlation Spectroscopy (PCS) 
Photon correlation spectroscopy (PCS), also called dynamic light scattering (DLS), is used for 
analysis of mean vesicles diameter of small-suspended vesicles, such as liposome vesicles. 
PCS measures the scattered light intensity at a 90° angle. The time dependent fluctuations in 
the intensity of scattered light, that results from vesicles (liposomes) random Brownian 
motion due to collisions between suspended vesicles and solvent molecules. The PCS 
instrument focuses laser light on sample, and it registers the movement from vesicles to 
solution. The analysis is based on time dependence of fluctuation. The small vesicles diffuse 
and move much faster than the large vesicles. Therefore; the rate of fluctuations of scattered 
light intensity vary accordingly (Torchilin and Weissig, 2003). PCS is a simple and rapid 
method to determine the particle size and size distribution of liposomes (Goldburg, 1999). 
 
1.6. Chloramphenicol as Model Drug  
Chloramphenicol (CAM), originally called Chloromycetin, was the first antimicrobial drug 
obtained from Streptyomyces species (Ehrlich et al., 1947). We applied CAM as model 
antimicrobial drug in this study. CAM is a neutral drug, since it contains both nitrogen and 
nonionic chlorine. It is stable at room temperature when stored in airtight container (Ehrlich et 
al., 1947). It degrades in solution due to exposure to light over longer time-period (Anderson 






Figure 5: Structure of chloramphenicol. 
This antimicrobial agent inhibits protein synthesis by binding to the large ribosomes subunits 
(50S) in microorganisms. CAM has a broad spectrum activity against both Gram positive and 
Gram negative bacteria, rickettsias and chlamydia (Anderson et al., 2012). CAM has effect on 
an array of bacteria (Helms and Quan, 2006). Although the applicability of CAM in the 
treatment of wound remain to be confirmed through broader clinical evaluation, preliminary 
results by Heal (Heal et al., 2009), indicate that a single administration of CAM ointment to 
suturated wounds after minor surgery procedure resulted in relative reduction in infection rate 
of about 40 %. 
 
CAM was selected as a model antimicrobial drug for this study, as its low aqueous solubility 
represents pharmaceutical challenge when applied in topical dosage form (Anderson et al., 
2012).  
 
1.7. Experimental design and multivariate analysis 
In fractional factorial deigns all combination factors are used to see if a change in variable 
could make a variation on the response or has an effect on the response. This design often 
gives much information as possible about the main effect of the design variables with a 
minimum of experiments. Due to this we were studied the main effect of the four variables 




By full factorial design it is enable to study the main effect of the individual variables, and all 
interaction between the combinations of two design variables with 2 or more factors. This 
study design is often used for extensive study of the effects of few variables, especially 
variables with more than two levels. In general the form to represent full factorial design n 
factors with two levels is; 2n  experiment. The general formula is pn, where p is denoting the 
number of the levels and n is denoting the number of factor that is investigated with p levels.  
This design is permitted the study of the interaction between designs variables based on the 
confounding pattern of the design (Esbensen et al., 2002). 
 
Multivariate data analysis is based on the statistical experimental principle of the multivariate 
statistics that involved many variables/factors and responses. It is used to perform the effects 
of all variables on the responses (Esbensen et al., 2002).   
In this thesis we have used factorial design and multivariate analysis for the optimization 
studies on probe sonication of liposome to get as much information as possible out of 






2. Aim of Study  
 
The main objective of this study was to investigate the robustness and optimize the probe 
sonication procedure applied for size reduction of liposomes used for topical drug delivery. 
Experiments were carried out using factorial design and multivariate analysis to investigating 
the effect of phospholipid concentration, number of sonication cycles, amount of propylene 
glycol added and total sample volume. Experiments with the most promising results in regard 
to liposome size from our design were investigated further by the addition of model drug 
CAM. Liposome size and drug entrapment efficiency was compared with results obtained 






3.  Material and Methods  
3.1. Materials 
3.1.1. Chemicals  
 
Table 2:  Chemicals 
Chemicals Purity/Quality  Manufacturer  
Acetic acid  ≥ 99.8 % Sigma-Aldrich, St. Louis, USA. 
Acetonitrile for HPLC  Sigma –Aldrich, Chemie Gmbh 
Steinheim, Germany. 
Chloramphenicol  ≥ 98 % Sigma-Aldrich, Steinheim, Germany  
Chloroform  99.0-99.4 % Sigma-Aldrich, St. Louis, USA. 
Disposable Culture tubes   Kimble Chase, USA 
Methanol ≥ 99.9 % Sigma-Aldrich, St. Louis, USA.  
Lipoid S 100 (soybean lecithin)  ≥ 94 % 
phosphatidylcholine 
Lipoid GmbH, Ludwigshafen, 
Germany.  
 
Potassium phosphate monobasic ≥ 99.0 % Sigma-Aldrich, St. Louis, USA. 
Propylene glycol  NMD A/S, Oslo, Norway 
Sodium chloride   Sigma-Aldrich, St. Louis, USA. 
Sodium phosphate dibasic ≥ 99.5 % Sigma- Aldrich 





3.1.2. Preparation of Phosphate Buffered Saline 
Phosphate buffered saline (PBS) pH 7.4 was composed of 8 g of sodium chloride (NaCl), 
0.19 g of potassium dihydrogen phosphate (KH2PO4) and 2.98 g of disodium hydrogen 
phosphate dihydrate (Na2HPO4.2H2O) were dissolved in 1000 ml of distilled water, and pH 
was adjusted to be pH 7.4 by using 1M HCl (Pavelic et al., 2005). 
The pH is measured using a pH-meter (Metrohm Ltd, Switzerland). Further, the solution was 
filtered through a 0.22 µm filter (Cellulose acetate filters Sartorius AG GmbH, Germany) 
before use.  
 
3.1.3. HPLC-mobile phase  
The mobile phase consist of 55 % Milli-Q water, 45 % MeOH, and 0.1 % acetic acid. The 
mobile phase was filtered through a 0.2 µm pore size filter prior to analysis (pharmacopeia, 




3.1.4. Instruments  
 
Table 3: Instruments 
Equipment  Model/Type  Producer  
Bath sonicator  Branson 5510  Branson ultrasonics cleaner, 
Danbury USA 
Büchi  waterbath  Büchi B-480 Büchi labortechnik, Flawil , 
Switzerland 
Büchi vacuum controller  Büchi vacuum controller B-721 Büchi, Switzerland 
Dialysis membrane  Visking, Size 1, Inf. Dia.8/32, 
6.3mm: 30 M (approx.) 





SpeedMixer DAC 150 FVZ SpeedMixer DAC 150 FVZ, 
Hauschild GmbH & Co KG, 
Hamm, Germany. 
HPLC Water e2795 Separation module  
Water 2489 UV/visible 
Detector  
XselectTM column C18- 2.5µm  
(3.0x75 mm). Software: 
Empower Pro, Empower3 
software, 2010, Water 
Corporation, Milford USA.  
 
Waters, Milford, USA 
Waters, Milford, USA 
 
Waters, Dublin, Ireland. 
Biocap LAF-bench Biocap RNA/DNA AC 230 V, 
50 Hz, 73 w 
Erlab, Val de Reuil, Cedex 
France 
Filter 0.22 µm non-sterile Syringe 
filters  
Pall Life Science, USA 
Filter 0.22 µm cellulose acetate filter Sartorius AG, Göttingen, 
Germany 
Milli-Q filtered water   
Milli-Q filter (0,22 𝜇m)  Merck Millipore KGaA, France 
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Distilled water   
Rotary-evaporator   Büchi rotavapor R-124 rotary 
evaporator with vacuum pump 
v-500- system 
Büchi, Switzerland  
PCS Submicron Particle Sizer, 
model 370. Software: CW 388 
Version 1.68, Nicomp, Santa 
Barbara, USA 
Nicomp particle sizing system, 
Santa Barbara, USA 
pH meter  744 pH meter Metrohm Metrohm Ltd., Switzerland 
Probe sonicator  Sonics high intensity ultrasonic 
processor 500 Watt model, 
Needle probe 13 mm 
 Sonics and Materials, USA 
Vortex Mixer Genie 2TM Bender & Hobein 
AG 







3.2 Preparation of liposomes 
3.2.1. Preparation of the lipid films 
Lipid films were prepared using two different film hydration methods depending on the final 
size reduction method applied: 
3.2.1.1.  Lipid film for sonication 
Briefly, soybean lecithin (Lipoid S 100, from Lipoide GmbH, Ludwigshafen, Germany) was 
dissolved in 20 ml of methanol and the organic solvent was removed by using a rotary 
evaporator with a vacuum pump system (Buchi, Switzerland) (Figure 6). When preparing 
drug containing liposomes CAM was also dissolved together with the lipid (Appendix 2). The 
solvent was removed from the dispersion at a pressure of 150 mbar for 20 minutes in water 
bath at 45 ±1°C. The pressure was adjusted to 50 mbar for about 1 hour to remove the traces 
of solvent and to obtain a dry film.  
 
 
Figure 6: Instrumentation for drying the lipid film rotary evaporator (2.) with a vacuum 




3.2.1.2. Lipid film for DAC 
Briefly, when making empty liposomes 200 mg lipoid S 100 was dissolved in 10 ml 
chloroform/methanol (2:1) in brown injection vial with 30 ml capacity. For drug containing 
liposomes 20 mg of CAM was added to the lipid solution. The organic solvent was removed 
by evaporation under a stream of N2-gass for 1 ½  hour. 
 
3.2.2. Hydration of lipid films 
The dried lipid films were hydrated according to the procedures described under. 
3.2.2.1 Hydration of lipid films for sonication 
The dry lipid films were hydrated with different amount of phosphate buffer saline (PBS pH 
7.4) and propylene glycol (PG), to form the liposomes dispersion. The lipid dispersion in the 
round bottom flask was mixed and shaken to ensure that all the lipids were evenly dispersed 
in the aqueous solvent. The dispersion was kept in a refrigerator at 4 °C overnight before size 
reduction and further characterization.  
 
3.2.2.2 Hydration of lipid films for DAC 
The lipid film for not containing PG was hydrated with 200 µl phosphate buffers saline (PBS 
7.4), and 14 glass beads added and mixed on vortex for 2 minutes. For PG-liposomes 100 µl 
PG was added together with 200 µl PBS. The dispersion in the vial was kept in a room 
temperature for 1 hour, and thereafter transferred to the refrigerator (4°C) overnight prior to 
size reduction and further characterization. 
 
3.2.3. Size reduction of liposomes  
For size reduction of liposomes, two different methods were applied as described under. 
3.2.3.1. Size reduction by probe sonication  
Probe sonication was used to reduce the original size of liposomes and the lamellarity of the 
liposomes in the dispersion after hydration of the lipid film. The needle dimension of probe 
sonicator was 13 mm, and it was carefully placed in the centre of the glass vial containing 
liposomes dispersion, expecting that the position of the probe may influence the ability to 
minimize the vesicle size (Antimisiaris et al., 2008). The liposome containing glass vial was 
immersed into a ice-bath for cooling, and the intensity was at 40 % amplitude. Sonication 
cycles time was standardized to 2 minutes, with 2 minutes resting time on ice-bath between 
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each cycle, to reduce the risk for lipid degradation. The liposomes dispersion was kept 
overnight in refrigerator at 4°C before the characterization.  
 
 
Figure 7: Picture of the probe sonicator applied in this study. 
 
3.2.3.2. Size reduction by DAC 
 
The dispersion was kept at a room temperature before homogenization of liposomes by using 
a DAC (SpeedMixer DAC 150 FVZ). The liposome dispersion without PG was run for 50 






Figure 8: schematic illustration of Dual asymmetric centrifuge (DAC) (Massing et al., 
2008). 
 
3.3. Characterization of Liposomes  
3.3.1. Drug entrapment and recovery  
To determine the entrapment efficiency for CAM, the liposomally unentrapped CAM was 
separated from the free drug by dialysis.  Dialysis was performed in dialysis tubing. The 
dialysis tube (Size 1, Inf. Dia. 8/32, 6.3 mm: 30 M Medicell, Membrane Ltd., London, UK.) 
was filled with CAM loaded liposome dispersion of 1 ml, and placed in a glass beaker 
containing 500 ml of PBS pH 7.4. The dialysis was performed for 4 hours. After dialysis, 
content of the dialysis bag was diluted 1:50 (V/V) and the dialysis medium (unentrapped 
drug) was dissolved 1:10 (V/V) in the HPLC-mobile phase. 
The efficiency of drug encapsulation and drug loading of liposomes were calculated 
according to equations below:  
Equation 1: 
Entrapment efficiency (EE %) =  
B
A
  x 100 
Where A is the quantified total amount of CAM in the liposome dispersion and in the dialysis 
medium, and B is amount of CAM in the dialysis bag measured after dialysis 
Equation 2: 
 Recovery (%) = 
𝐴
𝐶 
 x 100 
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Where A is the quantified total amount of CAM in the liposome dispersion and in the dialysis 
medium and C is the calculated amount of CAM that should have been present in the bag 
based on the weighted mass of CAM put into the formulation. 
 
3.3.2. HPLC quantification of chloramphenicol  
The standard curve was made from 20 mg/ml stock solution of chloramphenicol (20 mg 
CAM) in methanol (MeOH), by making standard solutions with concentration of 2.5, 5, 10, 
25, 50 and 100 𝜇g/ml. The standard solutions were prepared by diluting the stock solution by 
the mobile phase. The flow rate was set to 0.4 ml/min, and UV detector wavelength was 280 
nm. The column used was XTerraTM  RP C-18, and the temperature of the column was set to 
30°C, and the temperature of the samples was set to 30°C during the chromatographic 
separation. The total run time was 8 min, and the volume injected was 20 µl. All standard 






For quantification of CAM, HPLC was applied using the method described in 4.X.Y. As 
illustrated in Figure 9, the method gave a linear calibration curve, with a satisfactory linear 





























3.3.3. Liposome size analysis 
3.3.3.1. Photon correlation spectroscopy  
The vesicle size and size distribution of sonicated liposomes were determined by Photon 
correlation spectroscopy (PCS) on NICOMP™ model 370 (Santa Barbara, CA, USA). The 
vesicles were evaluated using volume weighted results and software was in vesicle mode 
NICOMP distribution appeared preferable over Gaussian distribution and was used to 
evaluate the data, as a chi-squared value < 3.0 is preferable for using the Gaussian mode. But 
as also the preferable value of a fit error of < 1.5 was exceeded for NICOMP. A low value of 
fit error indicates the accuracy and reproducible of the result, and also the relative stable or 
settled of the distribution analysis result. A Chi2-value describes the quality of the fit. When a 
Chi2-value is low the measured value deviate less from the expected frequency within the 
specific sample. According to obtain the needed lowest Chi2-value the baseline may adjust. 
Residual value over 10 describes the presence of aggregate particles that are not considered to 
be in the sample. In accordance to literature, the optimal value of residual may be as close as 
possible to zero (Frantzen et al., 2003).  
 
In order to avoid contamination from dust particles, the cuvettes (borosilicate glass) to be 
used for determination were filled with Milli-Q water and sonicated for 10 minutes in 
ultrasonic bath, and further rinsed with PBS pH 7.4 (0.2 µm pore size syringe filter) before 
use. The vesicle dispersion was diluted with freshly filtered PBS pH 7.4 until the intensity of 
250-350 kHz was achieved to ensure the accuracy and reproducible the analyzed results 
(Hupfeld et al., 2006).  
 
All samples were analysed three times. The analysis run time was 10 minutes. Vesicles mode 
was applied, and the temperature and viscosity were defined before each measurement. The 
temperature was 24±1℃  
PCS Parameters used: 
 Nicomp distribution /Gaussian distribution 
 Channel width: Auto set 
 Temperature/ Liquid viscosity: 23 ℃: 0.9325, 24 ℃: 0.9111, 25 ℃: 0.8904 
 Liquid index of refraction: 1.333 
 Intensity set point: 300 ± 50 kHz 
 Laser/ wavelength: Helium neon laser: 632.8 nm  
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 Scattering angle: 90℃ (fixed angle) 
 Toggle solid/vesicle particle: Vesicle particle 
 Number of cycle: 3 
 Run time: 10 minutes  
 
3.4. Experimental design and multivariate evaluation   
Four variables were investigated to identify the significance; sonication cycles (2, 4 and 6), 
total sample volume (2, 5 and 8 ml), lipid concentration (10, 20 and 30 mg/ml) and amount of 
propylene glycol (50, 125 and 200 µl). Table 7 shows the first 11 experiments of the 
fractional design that 8 experiments suggested for this study to produce by fraction factorial 
design 24-1 and expanded to 24 full factorial design (table 8 the 19 experiments) (Lundstedt et 
al., 1998).  
 
By taking into consideration all possible parameters that could influence the liposome size 
and during incorporation during probe sonication some of them were standardized.  
Moreover, reduced the number of experiments, statistical experimental design and statistical 
multivariate analysis of results that were used. For investigation of all variables two different 
levels (+1/-1) were applied in addition to center points in this study. Fractional factorial 
design 24-1 was applied to produce the firs 11 experiments, and determined which of the 
parameters that was most significant on vesicle size during probe sonication. Further, it was 
expanded to a full factorial design 24 to produce the 19 experiments based on the preliminary 
results for increasing the information of significant/ influential on vesicle size during probe 
sonication.  Hence, the four promising experiments were selected for further investigating the 
incorporation of CAM in the formulation   
 
3.5. Statistical evaluation  
The statistical data analyses were performed, and the p value of ≤  0,05 was considered 
statistically significant. 
ANOVA was used to study the main effects of all design variables in the multifactorial 
designs, and to evaluate the significance of effects on of the experiments variables on the 




4. Results and Discussion 
 
4.1. Manufacturing of liposomes by Dual Asymmetric Centrifugation (DAC)  
When starting this project, the initial goal was to establish a new DAC method for producing 
liposomes for topical application. This method was based on the previous described method 
by Massing and coworkers (Massing et al., 2008). As you can see in Table 4, we succeeded in 
producing liposomes with high entrapment > 50% and with the wanted size distribution of 
between 200-300 nm (Hurler et al., 2012). Since these two formulations have approximately 
the same size distribution, but totally different homogenization time at 2 minute and 55 
seconds with PG, and 50 minutes without PG. It demonstrates that PG makes the size 
reduction more efficient. It suggested that an interaction of PG with phospholipid bilayer 
allowing more bilayer flexibility and smaller vesicles as mentioned earlier by Manconi and 
her group (Manconi et al., 2009). Similar entrapment efficiency was resulted for CAM 
liposome with PG and CAM liposome without PG even if applying of PG increase the drug 
solubility in accordance to Bhalekar literature (Bhalekar et al., 2009).  Therefore, the results 
were considered not significant difference in entrapment efficiency between formulation with 
and without PG. The polydispersity index was reduced with longer mixing time, and this 
higher in liposomes added PG. 
 
 




Mean vesicle size  





    EE** 
 (% ± SD) 
CAM liposomes 282 ± 30.1 0.13 51.2 ± 2.3 
CAM liposomes with PG 230 ± 51 0.25 49.7 ± 2.8 
 
* Polydispersity index  ** Entrapment efficiency  
 
The values in Table 5 characteristic for different batches of liposomes without PG and the one 
given in Table 4, and we here investigated the effect of the storage in refrigerator overnight 
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on the measured size distribution and polydispersity. The liposome size distribution was 
found to be similar 1 hour after Speed Mixing and day after liposomes dispersion was kept in 
refrigerator, but of convenience we decided to the PCS measurements after one night storage. 
Entrapment efficiency and size distribution result was considered well reproducible when 
comparing with the same liposome described in Table 4.  
 
Table 5: Characterization of DAC liposomes 1 hour after Speed Mixing and after 
storage in refrigerator overnight. 
 
Freshly made liposomes 
 


















      
      EE ** 
(% ± SD) 
     
     RR***  










* Polydispersity index  ** Entrapment efficiency  *** Drug recovery  
 
After these initial trial productions we unfortunately had to stop using the DAC method as the 
machine broke down, and we needed to find an alternative method to DAC. We then chose to 
go for the probe sonication method. Since we were interested to produce the desire mean 
vesicle size between 200-300 nm, we wanted to learn what factors should be controlled in the 
process to obtain this liposome size distribution.  As tools for this we applied factorial design 
and multivariate analysis.    
 
4.2. Multifactorial design for sonication approach  
Based on the results from earlier experience on DAC-manufacturing regarding effect on PG 
on liposome size, and the need for having a reproducible method for small sample preparation 
of liposome using sonication, we decided investigate the effect of 4 different factors/design 
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variables on the vesicle size obtained after sonication (Table 6). To get as reproducible results 
as possible all other parameters were kept constant, such as sonication probe, amplitude, 
sample holder, length of sonication cycles (2 min). Table 6 represent the levels of the 
different variabels used in the factorial design, using the level (+1/-1) and centre points. 
 








Volume of propylene 
glycol (µL) 
High level (+1) 6 8 30 200 
0 4 5 20 125 
Low level (-1) 2 2 10 50 
 
 
4.2.1. Fractional factorial design (24-1 ) and multivariate analysis  
We decided to apply fractional factorial design, and using the Unscramble 9.8 software 
(Camo AS, Norway) a 24-1, the design, and the experimental set-up given was as described in 
Table 7. In the design we had 11 experiments, including the three centre points. In agreement 
with Lundsted by this design we could study the main effect of many variables (3 to 15) or 
several responses, but interaction can not be evaluated from this design (Lundstedt et al., 
1998). 
The 11 experiments from this design was carried out in randomize ordered and as numbered 
in the second column of Table 7. The table showed also the overview over the different 





Table 7: Design matrix for fractional factorial design (24-1) with center points. 
 

















1 8 -1 -1 -1 -1 
2 6 +1 -1 -1 -1 
3 9 -1 +1 -1 -1 
4 11 -1 -1 +1 -1 
5 10 +1 +1 -1 -1 
6 4 +1 -1 +1 -1 
7 2 -1 +1 +1 -1 
8 1 +1 +1 +1 -1 
CP 1 7 0 0 0 0 
CP 2 3 0 0 0 0 
CP 3 5 0 0 0 0 
 
 
Figure 10 showed the mean vesicles size that were determined by PCS from all 11 
experiments. Of these 11 liposome dispersion; dispersion no 1, 2 and 9 gave the promising 
mean vesicle size we were interested to investigate in this project, namely between 200-300 







Figure 10: Vesicle size with only the first 11 experiments. 
 
4.2.1.1. Standard deviation of probe sonication method   
As it is illustrated in Figure 11 the three center points are produced using the same 
composition and sonication conditions. Therefore, we would expect that all samples also 
should have the same vesicle size. But as you can see the actual mean vesicle size measured 
varied from 105.95 nm for CP1, 75.87 nm for CP2 and 89.38 nm for CP3. 
The standard deviation of the center points indicates the reproducibility and reliability of 
probe sonication method, and tells us that for a more accurate knowledge about the variables 
and their effect on our response, liposome size, more than one repetition of all exprements 































Figure 11: Vesicle size and P.I. for the three center points. 
 
4.2.1.2. Statistical evaluation of variables response on vesicle size 
 
To get more information out of the result we used ANOVA. And the results that were 
obtained represented in Figure 11. 
 
 
Figure 12: Regression coefficient and their confidence interval for response mean 




























Figure 12 indicates the regression coefficient and their confidence interval for response mean 
vesicle size. According to Figure 12, the sample volume has the biggest effect on the vesicle 
size of the four factors, with a p-value of 0.07 (Appendix 3). The p-value of ≤ 0.05 was 
considered statically significant. If we reduced the significance percentage criteria to 10 % 
sonication cycle wanted to be statically significant according to the ANOVA analysis results. 
Because of the lack of significance from these results we then decided to expand to a full 
factorial design, to see if this could improve the model and its resolution significance of the 
influence of the variables on the vesicle size from the sonication. 
 
4.2.2. Full-factorial design (24) and multivariate analysis  
When expanding the experimental design in to a full-factorial design, the resulting 
experimental set-up was as described in Table 8. The new experiments we had to execute are 
given in light blue. By full factorial design it is possible to study more closely the main effect 
of the individual variable on the response variables, as well as the effect of the interaction 





Table 8: Design matrix for full factorial design (24) with center points. 

















1 11 -1 -1 -1 -1 
2 12 +1 -1 -1 -1 
3 9 -1 +1 -1 -1 
4 10 -1 -1 +1 -1 
5 14 +1 +1 -1 -1 
6 17 +1 -1 +1 -1 
7 19 -1 +1 +1 -1 
8 15 +1 +1 +1 -1 
9 16 -1 -1 -1 +1 
10 8 +1 -1 -1 +1 
11 3 -1 +1 -1 +1 
12 4 +1 +1 -1 +1 
13 1 -1 -1 +1 +1 
14 2 +1 -1 +1 +1 
15 6 -1 +1 +1 +1 
16 7 +1 +1 +1 +1 
CP 1 5 0 0 0 0 
CP 2 18 0 0 0 0 
CP 3 13 0 0 0 0 
      
 
 
In Figure 13 all PCS results with mean vesicle size for the total 19 experiments included in 
full factorial design is given. From these result experiment 10 gave the aimed vesicle size, 






Figure 13: Vesicle size as measured by PCS for all 19 experiments included in full 
factorial design 24. 
The advantage of full factorial design is that we may estimate the main effect of all design 
variables and all interaction effects. Adding these 8 new experiments to the fractional design 
gave as expected more information regarding the effect of the experiment variables on the 
final liposome size. According to the ANOVA test (Figure 14), sample volume had a 
significant effect on the mean vesicle size with the p-value 0.0145. Number of sonication 
cycles and lipid concentration also were close to significant with the p-value of 0.0692 and 
0.7091, respectively. The variable that gave the least effect was the PG volume. This most 
suddenly can be explained by the relatively low concentration range investigated. This tells as 
that the lipid: PG ratio should be decreased in more diluted liposome dispersion as compared 
to vesicular phospholipids gels that we produced by DAC (Table 4). CAM liposomes with PG 
obtained size distribution after speed mixed in 2 minutes and 55 seconds compared with 50 
minutes when without PG. 
Also for the three other variables a more pronounced effect might be observed if there was 
more difference between the +1and the -1 level.  
 
The statistical model showed that sonication cycle and the interaction of sonication cycle and 






























decreased to 10 %. The statistical model that was used in this project would most probably 
have obtained more significant values with more repetition of the experiments. 
 
 
Figure 14: Regression coefficient and their confidence interval for response mean 
vesicle size. 
The chosen experiments for further use with CAM were experiment; 1, 2, 9 and 10, since the 
size we aimed to investigate this drug incorporation should have a size range between 250-
350 nm.  
 
4.3. Drug loaded sonicated liposomes   
The CAM-liposomes was prepared in the same way as the empty liposome. The only 
difference was that CAM was added to the lipid solution before when making the lipid film. 
The entrapment efficiency was determined by using dialysis method for separation of the 
unentrapped drug from liposomes containing drugs (Pavelic et al., 1999). The lipid drug ratio 
was the same for all formulations (Appendix 2). The mean vesicle size and polydispersity 
index was determined by PCS method. Characteristic for CAM containing liposomes 










Ordered*   
       
     EE 







      
      RR 
 (%  ± SD)  
1 30.13 ± 0.15 0.512 836.07 88.09 ± 0.39 
2 31.05 ± 0.06 0.352 67.10 101.51 ± 0.51 
9 26.00 ± 0.02 0.479 834.93 104.02 ± 0.69 
10 22.98 ± 0.12 0.498 768.60 101.47 ± 0.67 
 
* Refers to empty liposomes in full factorial design given in Table 8. 
 
As it is shown in Table 9, three of the four liposome dispersions were, as expected, larger in 
size in the presence of CAM, than for the corresponding experiments we had with empty 
liposomes. CAM has low aqueous solubility thus will incorporated in the lipid bilayer, and 
has therefore been described in the literature to make liposome vesicles more resistance to the 
size reduction (Anderson et al., 2012). Experiment number 2 gave unexpected small vesicle 
size at 67.10 nm, knowing that empty liposomes with the same experimental conditions had a 
mean vesicle size 252.58 nm. If we compared the four experiments results in Table 9, all 
experiment had the same lipid concentration, sample volume and drug concentration. The 
only factors that differ between these experiments were number of sonication cycles 
(experiment 1 and 9 had 2 sonication cycle, whereas experiment 2 and 10 had 6 sonication 
cycles), and added volume of PG (for experiment 1 and 2 was 50 µl, whereas exp. 9 and 10 
had 200 µl). For more details you can have a look in Appendix 2.  The high number of 
sonication cycles of 6, relative to experiments 1 and 9 with only 2 sonications cycles could 
explain the relative smaller size. However, experiment 2 had less PG volume 50 µl then 
experiment 10  had 200 µl which the oppsite of what we would expect. The conclusion that 
had to be related to experimantal errors during probe sonication such as probe position that 
might influence the ablity to minimize the vesicle size as mentioned earlier by Antimisiaris 




As the results showed in Table 9, experiment 1 gave higher entrapment efficiency at 30.13 % 
in comparison with experiment 9 that had 26 % entrapment efficiency, and these two 
experiments were sonicated in 2 sonication cycles, whereas the experiments were containing 
different amount of PG volume. Experiment number 2 gave the highest entrapment efficiency 
of 31.05 % even if this experiment had low mean vesicle size. Generally we observed the four 
experiments had quit similar entrapment efficiency between 23-31 %. 
 
According to literature (Bhalekar et al., 2009) a high amount of drug could be incorporated in 
liposome dispersion due to lipid solubility of the drug. And according to our result the larger 
liposomes have more capacity of drug incorporation than the smaller liposomes. When using 
DAC method the vesicle size resulted 263.07 nm, while probe sonication method resulted 
larger vesicle size. We thus should expect that the sonicated liposomes had a higher drug 
entrapment than the DAC-liposomes. The fact that the opposite is found can however be 
explained by the higher lipid content in the DAC-liposomes.  
 
DAC resulted more EE % according to when the lipid film was hydrated by PBS pH 7.4 there 
was low volume of PBS and low amount of CAM in the aqueous medium. Therefore, it was 
more incorporation of CAM in lipid membrane, while the sonication method had more PBS 
volume and the most of the drug (CAM) was in PBS (aqueous medium) than in lipid 
membrane. The more CAM in aqueous medium lead to the more dissolving of CAM and the 
less capacity of CAM incorporation in the lipid membrane. Due to the results, DAC method 
seemed to be found gentler than sonication method.  
 
The recovery of the drug was determined for the all probe-sonicated samples, and it was 
found to be between 88.09 and 104.02 % of the total amount that was used for preparation of 
the formulations. The drug recovery was found to be lower in sample 8 in comparison to the 







5. Conclusion  
 
We have demonstrated that both DAC and probe sonication are suitable methods for making 
liposomes with a desired size range of between 200 and 300 nm. DAC is favored by a higher 
incorporation efficiency for the model drug applied here, chloramphenicol (CAM). Statistical 
experimental design and multivariate analysis were applied successfully, and confirmed that 
samples volume and number of sonication cycles are the most responding variable with 
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6. Perspectives  
 
 New experiments with less gentle sonication conditions should be performed with 
CAM-liposomes to reach the aimed size distribution.  
 Propylene glycol concentrations in sonication should be increased to look for effect on 
needed sonication time for sufficient size reduction and to investigate effect drug 
entrapment. 
 Liposomes with the bet size distribution and drug entrapment should be combined 
with a suitable vehicle for topical application.  
 A wider range for some of the variables used might give more information on their 
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Appendix 1 * 
 
 
Appendix* Liposome size results of 19 experiments PCS measurement carried out day after 








SD (nm) Variance 
(P.I) 
Fit error 
1 8 305.47 8.32 0.38 1.97 
2 14 252.58 1.90 0.34 2.61 
3 16 133.59 5.18 0.32 3.04 
4 11 99.82 1.23 0.33 2.63 
5 12 407.79 7.57 0.39 2.22 
6 4 96.74 1.65 0.31 2.55 
7 2 112.31 1.31 0.31 2.35 
8 13 68.37 1.35 0.37 3.09 
9 17 254.30 3.21 0.39 2.05 
10 6 302.68 5.08 0.35 2.16 
11 9 121.87 2.35 0.31 2.31 
12 15 95.79 2.15 0.31 2.95 
13 10 876.65 36.37 0.59 2.34 
14 18 85.84 2.37 0.32 2.73 
15 19 106.55 4.96 0.33 3.19 
16 1 55.84 0.87 0.33 2.83 
CP 1 3 105.94 1.52 0.32 2.36 
CP 2 5 75.87 0.36 0.36 2.77 




Overview over the composition of the CAM- and PL-solution prior to making the lipid 




















1 11 2 2 1 10 50 
2 12 6 2 1 10 50 
9 16 2 2 1 10 200 
10 8 6 2 1 10 200 
Appendix  2 
ANOVA mean particle size and analysis of mean particles size as response 
ANOVA  DF MS F-ratio p-value  
Summary      
Model  4.0000 78511.7000 3.0595 0.0525 
Error  14.0000 25662.0200   
Corr. Total  18.0000    
Variables      
Sonication cycle  1.0000 99362.0800 3.8720 0.0692 
Sample volume  1.0000 199788.9000 7.7854 0.0145 
Lipid concentration  1.0000 3720.6960 0.1450 0.7091 
PG volume  1.0000 11175.1300 0.4355 0.5200 
Model check      
Mean      
Linear  4.0000 78511.7000 3.0595 0.0525 
Lack of Fit      
Lack of fit 12.0000 299901.2200 131.8242 0.0076 
Pure error 2.0000 226.8264   
Error 14.0000 25662.0200   




Appendix  3 
summary of ANOVA results of full factorial design 
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